Viridian Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Viridian Therapeutics wird ein Gewinn- und Umsatzwachstum von 32.1% bzw. 78.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 35.9% pro Jahr wachsen soll.

Wichtige Informationen

32.1%

Wachstumsrate der Gewinne

35.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	78.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:1S1 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	50	-341	-260	-250	9
12/31/2025	0	-327	-282	-299	13
12/31/2024	0	-268	-207	-202	13
9/30/2024	0	-257	-197	-197	N/A
6/30/2024	0	-228	-169	-168	N/A
3/31/2024	0	-218	-168	-167	N/A
12/31/2023	0	-238	-185	-184	N/A
9/30/2023	0	-217	-181	-180	N/A
6/30/2023	1	-198	-163	-162	N/A
3/31/2023	2	-172	-136	-135	N/A
12/31/2022	2	-130	-95	-94	N/A
9/30/2022	2	-113	-77	-76	N/A
6/30/2022	1	-98	-68	-68	N/A
3/31/2022	2	-87	-65	-64	N/A
12/31/2021	3	-79	-55	-55	N/A
9/30/2021	3	-141	-48	-47	N/A
6/30/2021	3	-133	-41	-41	N/A
3/31/2021	2	-121	-33	-33	N/A
12/31/2020	1	-111	-30	-30	N/A
9/30/2020	2	-30	-28	-28	N/A
6/30/2020	3	-36	-32	-32	N/A
3/31/2020	5	-38	-33	-33	N/A
12/31/2019	4	-42	-36	-36	N/A
9/30/2019	4	-42	-37	-36	N/A
6/30/2019	4	-40	-34	-34	N/A
3/31/2019	4	-40	-32	-31	N/A
12/31/2018	8	-33	-27	-27	N/A
9/30/2018	9	-29	-26	-26	N/A
6/30/2018	10	-26	N/A	-25	N/A
3/31/2018	8	-24	N/A	-27	N/A
12/31/2017	4	-27	N/A	-28	N/A
9/30/2017	3	-26	N/A	-24	N/A
6/30/2017	3	-24	N/A	-21	N/A
3/31/2017	3	-21	N/A	-19	N/A
12/31/2016	3	-17	N/A	-15	N/A
9/30/2016	4	-17	N/A	-14	N/A
12/31/2015	5	-16	N/A	-13	N/A
12/31/2014	8	-6	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1S1 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 1S1 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 1S1 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 1S1Die Einnahmen des Unternehmens (78.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.6% pro Jahr).

Hohe Wachstumseinnahmen: 1S1Die Einnahmen des Unternehmens (78.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1S1 in 3 Jahren voraussichtlich hoch sein wird

Viridian Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: US$1.16 loss per share (vs US$1.09 loss in 3Q 2023)

CEO, President & Director recently bought €447k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

First half 2024 earnings released: US$1.82 loss per share (vs US$2.88 loss in 1H 2023)

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought €92k worth of stock

President recently bought €149k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

First quarter 2022 earnings released: US$0.98 loss per share (vs US$2.91 loss in 1Q 2021)

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$2.22 loss per share (vs US$1.82 loss in 2Q 2020)

Independent Director Joseph Turner has left the company

Independent Chairman of the Board Jeffrey Hatfield has left the company

CFO, Secretary & Treasurer has left the company

First quarter 2021 earnings released: US$2.91 loss per share (vs US$2.65 loss in 1Q 2020)

Full year 2020 earnings released: US$31.13 loss per share (vs US$20.04 loss in FY 2019)

New 90-day low: €12.68

Viridian Therapeutics, Inc. Appoints Jonathan Violin, as Chief Executive Officer

miRagen Therapeutics, Inc. Announces Executive Changes

New 90-day high: €18.14

Miragen Therapeutics, Inc. Enters into License Agreement with Xencor for Use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Miragen Therapeutics, Inc. Announces Diana Escolar, M.D. to Resign as the Chief Medical Officer of the Company, Effective as of January 1, 2021

Revenue misses expectations

New 90-day high: €1.04

Miragen Therapeutics, Inc. (NasdaqCM:MGEN) acquired Viridian Therapeutics, Inc. for approximately $110 million.

Miragen Therapeutics, Inc. Announces Management Changes

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken